or Try an Advanced Search...

    Technical Analysis for JAGX - Jaguar Animal Health, Inc.

    Grade Last Price % Change Price Change
    C 0.27 -10.27% -0.03
    JAGX closed down 10.27 percent on Wednesday, May 8, 2024, on 25 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: May 13
    *** please verify all earnings dates ***
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Up
    Historical JAGX trend table...
    Date Alert Name Type % Chg
    1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Calm After Storm Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Gapped Down Weakness 0.00%
    Calm After Storm Range Contraction -10.27%
    Upper Bollinger Band Walk Strength -10.27%
    Wide Bands Range Expansion -10.27%
    Older End-of-Day Signals for JAGX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 15 hours ago
    Fell Below Previous Day's Low about 19 hours ago
    Down 10% about 19 hours ago
    Gap Down Partially Closed about 19 hours ago
    Gapped Down (Partial) about 19 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    JAGX Chart by TradingView
    Basic chart:

    Profile

    Jaguar Animal Health, Inc. Description

    Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Gastrointestinal Animal Health Dog Gastroenterology Prescription Drugs Colitis Drug Products Diarrhea Gastrointestinal Tract Gastrointestinal Products

    Is JAGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
    May 6 Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
    May 3 Why Apple Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
    Apr 29 Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
    Apr 22 Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
    Apr 18 Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
    Apr 16 Jaguar stock rallies 54% on licensing deal for chemo support drug
    Apr 16 Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
    Apr 10 S&P 500 Down 1%; Delta Air Lines Posts Upbeat Earnings
    Apr 10 Jaguar Health shareholders approve reverse stock split
    See more JAGX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.22
    52 Week Low 0.0512
    Average Volume 80,146,368
    200-Day Moving Average 0.25
    50-Day Moving Average 0.13
    20-Day Moving Average 0.20
    10-Day Moving Average 0.25
    Average True Range 0.04
    RSI (14) 66.10
    ADX 61.3
    +DI 38.92
    -DI 10.03
    Chandelier Exit (Long, 3 ATRs) 0.24
    Chandelier Exit (Short, 3 ATRs) 0.20
    Upper Bollinger Bands 0.33
    Lower Bollinger Band 0.07
    Percent B (%b) 0.76
    BandWidth 131.23
    MACD Line 0.05
    MACD Signal Line 0.04
    MACD Histogram 0.0092
    Fundamentals Value
    Market Cap 13.57 Million
    Num Shares 50.8 Million
    EPS -0.87
    Price-to-Earnings (P/E) Ratio -0.31
    Price-to-Sales 0.46
    Price-to-Book 3.12
    PEG Ratio -0.02
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.30
    Resistance 3 (R3) 0.31 0.30 0.30
    Resistance 2 (R2) 0.30 0.29 0.30 0.30
    Resistance 1 (R1) 0.28 0.28 0.28 0.28 0.29
    Pivot Point 0.27 0.27 0.27 0.27 0.27
    Support 1 (S1) 0.26 0.26 0.25 0.26 0.24
    Support 2 (S2) 0.25 0.26 0.25 0.24
    Support 3 (S3) 0.23 0.25 0.24
    Support 4 (S4) 0.23